Comparative Pharmacology
Head-to-head clinical analysis: GALLIUM CITRATE GA 67 versus MACROTEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GALLIUM CITRATE GA 67 versus MACROTEC.
GALLIUM CITRATE GA 67 vs MACROTEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gallium citrate Ga 67 is a radiopharmaceutical that localizes in tumors and inflammatory lesions. The mechanism is not fully understood but may involve binding to transferrin and uptake via transferrin receptors, as well as accumulation in lysosomes of macrophages and tumor cells.
Not applicable for diagnostic use.
2-5 mCi (74-185 MBq) intravenously once; repeat imaging may require an additional 2-5 mCi at 48-72 hours.
5 mCi (185 MBq) intravenously as a single dose for lung perfusion imaging.
None Documented
None Documented
Terminal elimination half-life: approximately 25 days (range 6-72 days) in soft tissues; reflects slow clearance from binding sites (e.g., transferrin, lactoferrin).
6 hours; prolonged in renal impairment (up to 30 hours in ESRD)
Renal: approximately 25% within first 24 hours; fecal: approximately 10% within 48 hours; retained in tissues (bone, liver, spleen) with slow release over weeks.
Renal: 95% as unchanged drug; biliary/fecal: <5% as metabolites
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical